Concert Pharmaceuticals trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is Roger D. Tung. Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It aims to discover and develop small-molecule drugs for new treatments to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, and Alzheimer’s agitation.



Previous Intraday Performance:

The CNCE shares had a previous change of 0.21% which opened at 9.42 and closed at 9.46. It moved to an intraday high of 9.63 and a low of 9.21.

SeekingAlpha:  Key events next week – healthcare

Historical Performance:

Over the last five trading days, CNCE shares returned -4.06% and in the past 30 trading days it returned -43.66%. Over three months, it changed -33.75%. In one year it has changed -49.81% and within that year its 52-week high was 21.00 and its 52-week low was 9.21. CNCE stock is 2.71% above its 52 Week Low.

Our calculations result in a 200 day moving average of 14.49 and a 50 day moving average of 13.94. Right now, CNCE stock is trading -34.72% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Key events next week – healthcare

Liquidity:

The company has a market cap of $222.6m with 23.5m shares outstanding and a float of 22.4m shares. Trading volume was 177,414 shares and has experienced an average volume of 449,325 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Concert Pharmaceuticals was -2.39 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.62.

The next earnings report will be: 04-25-2019

The growth of the EPS is critical in understanding the current valuation of Concert Pharmaceuticals; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -92.70% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 4.90% of insider ownership and 95.30% of institutional ownership.



I calculated the beta to be 0.90

SeekingAlpha:  Destination Maternity reports Q4 results

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -30.77%, return on assets is -27.72%, price-to-sales is 8,542.93 and price-to-book is 1.32.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here